

**Amendments to the Claims:**

This claim listing will replace all prior versions and listings of claims in the application:

**Claim Listing:**

- 1-19. (Cancelled)
20. (Currently Amended) An immunostimulatory oligonucleotide compound, comprising:
- an immunostimulatory dinucleotide of formula CpG 5'-pyrimidine-purine-3', wherein ~~pyrimidine~~ C is a ~~natural or non-natural~~ pyrimidine nucleoside and ~~purine~~ G is a natural or non-natural purine nucleoside, and wherein p is an internucleotide linkage selected from the group consisting of phosphodiester, phosphorothioate and phosphorodithioate;
- a 3'-3' linkage; and
- one or two accessible 5' ends;
- provided that the oligonucleotide is not complementary to the *gag* or *tat* gene of HIV-1.
21. (Original) The immunostimulatory oligonucleotide compound of claim 20, which oligonucleotide comprises two accessible 5' ends.
22. (Canceled)
- 23-38. (Cancelled)
39. (New) An immunostimulatory oligonucleotide compound, comprising:
- an immunostimulatory dinucleotide of formula CpG, wherein C is a natural pyrimidine nucleoside and G is a non-natural purine nucleoside, and wherein p is an internucleotide linkage selected from the group consisting of phosphodiester, phosphorothioate and phosphorodithioate;
- a 3'-3' linkage; and
- one or two accessible 5' ends;

provided that the oligonucleotide is not complementary to the *gag* or *tat* gene of HIV-1.

40. (New) The immunostimulatory oligonucleotide compound of claim 20, which oligonucleotide comprises two accessible 5' ends.